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Summary 
Here we have carried out a multiparameter analysis using a panel of 28 immunohistochemical 
markers to identify markers of transformation from benign and dysplastic naevus to primary 
melanoma in three separate cohorts totaling 279 lesions. We have identified a set of eight 
markers that distinguish naevi from melanoma.  None of markers or parameters assessed 
differentiated benign from dysplastic naevi. Indeed, the naevi clustered tightly in terms of 
their immunostaining patterns whereas primary melanomas showed more diverse staining 
patterns. A small subset of histopathologically benign lesions had elevated levels of multiple 
markers associated with melanoma, suggesting that these represent naevi with an increased 
potential for transformation to melanoma.  
Significance 
Up to 50% of melanomas are derived from naevi, although the potential for an individual 
naevus to transform to melanoma is exceedingly low. The question of which naevi have the 
potential to transform to melanoma is currently based on clinical guidelines and the 
experience of the clinician. There is currently no evidence for the existence of naevi that have 
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accumulated molecular alterations normally associated melanoma, and thus represent a 
potential reservoir of high risk pre-cancers.   Here we have investigated known markers 
associated melanoma formation and identified a subset of naevi that appear to have elevated 
transformation potential.   
 
Introduction 
Despite the recent advances in treatment, 5 year survival in late stage melanoma remains very 
low, but if it is detected early, melanoma is curable. Current clinical practice relies on the 
detection of early melanoma and changing naevi – a clue that malignant transformation of 
melanocytes to melanoma is underway. Whilst the phenotypic features of this transformation 
are well recognized, the molecular mechanisms underlying these changes remain elusive.  
 
 There are divergent pathways for the development of melanoma, those that develop 
on chronically sun exposed sites, and those on sites of intermittent exposure (Whiteman et al., 
2003).  The latter are associated with BRAF, and to a slightly lesser extent NRAS mutations, 
and increased nevus counts (Walker, 2008), with high numbers of naevi (>60) being one of 
the strongest risk factors for the development of melanoma. While 20-50% of melanomas 
develop from naevi, few become melanoma and clinically it is difficult to predict which 
naevus is likely to undergo neoplastic change. This is particularly important for high-risk 
dysplastic naevus syndrome (DNS) patients where excision of all naevi is not feasible. The 
ability to identify and treat naevi which were likely to become melanoma could significantly 
reduce melanoma rates in the general population, particularly the high risk DNS population.  
The clinical problem is to identify the naevi with high transformation potential for treatment. 
The existence of a population of “partially transformed” naevi has not been demonstrated as 
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these lesions will have a similar appearance on normal histopathological assessment as 
benign lesions. However, at the molecular level they are likely to have altered pathways that 
could contribute to neoplastic transformation, but dysregulation of other pathways to drive 
transformation. Multiple molecular pathways have been implicated in the pathogenesis of 
melanoma, but the temporal and spatial sequence of events is not well established. Like many 
cancers, melanoma is thought to result from the accumulation of genetic alterations within a 
single cell, until it attains malignant potential. Alterations in the p16/CDK4/RB (Castellano et 
al., 1997) and MAP kinase pathways (de Snoo and Hayward, 2005; Hodis et al., 2012), PI3K, 
p53 (Avery-Kiejda et al., 2011), and β-Catenin/Notch (Bachmann et al., 2005) pathways have 
been described. Many of these altered pathways have also been report in naevi.  For example, 
either oncogenic NRAS or BRAF mutations are present in the majority of naevi, although a 
significant proportion of melanomas are wild type for both these genes (Hodis et al., 2012; 
Pollock et al., 2003).  Thus, individually altered pathways associated with melanoma can be 
insufficient to indicate the transformation potential of an individual naevus.   
 
 Many previous studies have identified single markers that are implicated in the 
progression to melanoma. However, very few studies have used large-scale tissue microarray 
analysis to determine the role of a panel of markers in malignant transformation. Here we 
have examined differential expression of 28 molecular markers from pathways previously 
implicated in melanoma development, to investigate whether there is a subset of 
histologically benign naevi that expressed markers associated with transformation to 
melanoma. Using our observations from the staining patterns of these molecular markers, we 
have defined a set of markers that  differentiate between naevi and melanomas, and identified 
a small proportion of naevi with alterations of a subset of markers that are normally strongly 
associated with transformation.   
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
Results 
Markers of Transformation 
To identify markers that discriminate between pre-malignant naevus and the transformed 
state of primary melanoma, we assessed a total of 28 molecular markers using tissue 
microarrays to refine a large set of tumour intrinsic markers. The useful markers from this 
screen were validated on a set of full width lesions, with an additional set of 
microenvironment localised markers identified from the literature with potential to 
discriminate between naevus and melanoma. The most discriminatory set of markers from 
this analysis where then further validated in an independent set of full width lesions 
(Supplementary Figure S1).   A total of 21 markers identified in the literature as being altered 
during progression to melanoma were initially assessed for their ability to discriminate 
between naevus and melanoma using tissue microarrays representing the spectrum from 
benign naevus to metastatic melanoma (Supplementary Table S1).  A number of these 
markers FAPB-7, -H2Ax, APE1, p53, Cyclin D1, COX2, phospho-STAT3, Survivin and 
MITF) failed to discriminate between naevus and primary melanoma, and were thus excluded 
from further analysis.  The remaining 12 markers were assessed semi-quantitatively using a 
larger TMA with 100 lesions represented in three cores each lesion.  The number of samples 
and their diagnosis is shown in Supplementary Table S2 and S3.    
 
 Initial inspection revealed that for the majority of markers, there was little difference 
in the staining of benign and dysplastic naevus.  This was clearly demonstrated by a 
comparison of H Scores for these markers (Supplementary Figure S2A, B).  The univariate 
analysis identified nine markers significantly different between the combined naevus (benign, 
dysplastic) and primary melanoma (thin, thick; Supplementary Table S4; false discovery rate 
(FDR) ≤ 0.05).  To complement this analysis, the multivariate statistical method random 
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Forest identified these same parameters as the strongest discriminators, although in a slightly 
different order (Supplementary Figure S3).  However, when the H Scores for each marker 
were assessed for each diagnosis category, the majority of these revealed that they most 
changed between thin and thick primary melanomas (Supplementary Figure S2A, B).  Five of 
these markers were strongly associated with thick melanomas, lymph node and distant 
metastasis, including -Catenin, E-Cadherin and c-KIT which decreased in total intensity, 
and Nestin and MCAM which increased in intensity from thin to thick melanoma.  BRN2 and 
CDK6 were more weakly associated with this latter trend. This pattern of expression 
suggested that these are likely to represent markers of increased tumor growth and/or 
metastasis.  The markers with the strongest correlation with the transformation from 
dysplastic nevus to thin primary melanoma were p16 and HMGB2, both of which had 
reduced staining associated with transformation. Typical staining patterns p16 and HMGB2 
in naevus and thin melanomas are shown in Figure 1, and typical staining for a selection of 
other markers in the TMAs is shown in Supplementary Figure S4.     
 
 The eight most informative markers from the TMA analysis, including c-KIT, -
Catenin, and BRN2,  were taken forward to further analysis in a separate panel of 95 full-
width lesion representing the spectrum from benign naevus to thick melanoma. An additional 
seven markers identified from the literature including stromal markers such as 
D240/podoplanin as a marker of lymph angiogenesis, and CD31 for angiogenesis, were also 
assessed. The markers assessed, numbers and diagnosis of lesions in this set is reported in 
Supplementary Table S5 and S6.  Examples of the typical staining pattern for each marker in 
naevus and melanoma are shown in Supplementary Figure S5.   
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 Preliminary analysis of the additional markers showed N-Cadherin, PTEN, Ki67 and 
D240 strongly discriminated between naevus and melanoma with p values < 0.0001 (Mann 
Whitney test).  BRaf V600E staining revealed the expected frequency in each diagnosis, with 
62% of nevus (35/57) and 38% melanomas (15/39) staining positive. Univariate statistical 
analysis of all the naevi versus all melanomas combined provided very similar results to 
analysis of dysplastic naevi versus thin melanomas only, thus only the latter analysis is 
shown (Table 1). This revealed the number of D240 lymphatic vessels was one of the 
strongest indicators of transformation along with gain of nuclear N-Cadherin and loss of 
PTEN staining, absence of nuclear -Catenin and p16 staining, increased CD68 macrophages 
and loss of HMGB2 staining. The gain or loss of nuclear N-Cadherin, p16 and -Catenin 
were independent of the staining intensity of these markers.   
 
 Unsupervised multivariate analysis with multiple Correspondence Analysis (MCA) 
based on all significant staining parameters identified previously showed that naevi were 
clustered away from the thin and thick primary melanomas, with the in situ melanomas 
clustering across these two groups (Figure 2).  Along the first MCA component, the majority 
of naevi, benign and dysplastic, clustered tightly whereas the melanomas although clearly 
separated from naevi, were more dispersed, indicating a significant degree of divergence in 
their staining patterns.  The second MCA component highlighted a subset of naevi that did 
well separate from the majority of naevi, indicating significant divergence from the normal 
staining of naevi, and have acquired some of the changes associated with melanomas.   
 
 Prior to Random Forest statistical analysis, the continuous variable Ki67 and D240 
were converted to categorical variables to enable this analysis (Supplementary Figure S6). 
While this cut off provided a clear distinction between naevus and melanoma with Ki67 
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staining, it was more ambiguous for D240.  Random Forest analysis identified the same set of 
strongly discriminatory markers in separate analysis of the combined naevi versus combined 
melanomas, and dysplastic naevi versus thin primary melanomas, although in a slightly 
different order. Stability analysis likewise demonstrated that Ki67, gain of N-Cadherin 
nuclear staining, PTEN % cells and score, loss of -Catenin and p16 nuclear staining were 
the strongest discriminators of transformation to melanoma from dysplastic naevus. 
Combined, these parameters had a sensitivity of 93% and specificity of 79%, with an error 
rate of 13% (Supplementary Table S7).   
 
  Another feature of the skin sections that was readily discerned was the degree of 
elastosis. Scoring the lesions for elastosis revealed a significant degree of difference between 
the naevus and melanoma groups, with the majority of naevi showing Elastosis scores 1-2  
while the primary melanomas had a greater range but overall a higher Elastosis score 
(Supplementary Figure S7A). A high proportion of the higher Elastosis scores were 
associated with lesions from areas of chronic sun damage, but this was not exclusively the 
case.  There were differences in average ages of the naevus and melanoma patients as 
expected, with the naevus average of 43.5 ±18 y, and melanoma 63.8 ± 17 y.  This 
corresponded to the difference in solar elastosis score of naevus 1.4 ±0.7 and melanoma 2.6 
±1.1 (p < 0.0001).  There were no differences based on sex, and the differences in 
immunostaining and solar elastosis were independent of age of the subject.   
 
 These top eight discriminating parameters, plus the Elastosis score were assessed to 
determine the minimal number of parameters required to predict transformation. The PTEN 
% cells, score and nuclear localization were combined as the H score to reduce this to seven 
parameters (Table 2; Figure 3). The Elastosis score was a significant discriminator between 
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naevus and melanoma (Supplementary Figure S7B).  We established a Transformation score 
to each lesion, where a score of 1 was assigned in the following cases: 3  or more D240 
vessels, score of 2 or more Ki67, PTEN H score ≤ 4, the presence of nuclear N-Cadherin 
staining, absence of nuclear p16, absence  of nuclear -Catenin staining, and elastosis score 
greater than 1 to give  a maximum score of seven (Table 2).  It was found that 32/36 (89%) of 
melanomas had a score of four or more, whereas only 4/57 (7%) of naevus had a 
Transformation score  of 4 or more (Figure 4A).  The four melanomas with a score less than 
four all had ≤ 2% Ki67 positive cells, nuclear -Catenin, no nuclear N-Cadherin and elevated 
PTEN levels, indicating weakly proliferating/indolent melanomas. The highest scoring naevi 
had lost nuclear -Catenin, gained nuclear N-Cadherin, but retained nuclear p16. These may 
represent naevi with a strong potential for transformation. Addition of the BRAF mutation 
status did not increase the power of these features to discriminate between nevus and 
melanoma.   
 
 This seven marker set was analysed in a separate validation set of 62 full width 
lesions representing naevus and primary melanoma (Supplementary Table S8 and S9).  These 
were stained with the six markers identified above and for elastosis, scored, and the 
Transformation score calculated based on the same parameters as in Table 2. Again there was 
a significant difference between naevi and melanomas (Figure 4B). The higher scoring naevi 
(3-5) had high elastosis scores and ≤ 2% Ki67 positive cells suggesting higher levels of sun 
exposure and a more highly proliferative state (Figure 4B), whereas the lower scoring 
melanomas (3) often had low elastosis scores and no nuclear N-Cadherin.  Random forest 
analysis was performed on the pooled naevi (benign and dysplastic) and melanomas (in situ 
and primary) for identifying naevus and melanoma.   This produced a 16% classification 
error rate, all the misclassified lesions were naevi, classified as melanoma (Table 3). The 
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significance of the difference in Transformation scores for the pooled naevi and pool 
melanomas for both data sets was p <0.0001 (Mann Whitney U test).    
 
Discussion 
Here we have assessed a large panel of previously identified markers of transformation to 
melanoma to determine whether multiparameter analysis of melanocytic lesions could better 
identify naevi that displayed markers normally associated with the transformation to 
melanoma.  We have shown using seven markers, including the level of solar elastosis as a 
surrogate marker of UV exposure, that when combined they discriminated between naevi and 
thin primary melanomas. This set of markers was demonstrated to have discrimination in an 
independent validation set of melanocytic lesions. Although these markers may be useful in 
providing a molecular signature of melanoma, it was clear that they did not perform 
significantly better than conventional histopathologic diagnosis. However, the study did 
provide useful insights into the different classifications currently used for these melanocytic 
lesions, and more importantly identified a subset of histopathologically benign naevi that had 
accumulated markers strongly associated with the transformed phenotype. 
 
  A number of features stood out from this study.  The first was that with the large 
panel of markers used in this study it was not possible to discriminate between benign and 
dysplastic naevi. The classification of dysplastic naevus is controversial, and recently the 
justification for such a classification has been questioned (Hurwitz and Tavel, 2015; 
Rosendahl et al., 2015).  Currently, dysplastic naevi are defined clinically as well as 
histopathologically based on the original work of Elder in 1980 (Elder et al., 1980).  
However, the majority of epidemiological studies do not discriminate between benign and 
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dysplastic naevi, and these studies provide evidence for an increased number of naevi 
associate with increased melanoma risk (Olsen et al., 2010; Usher-Smith et al., 2014). The 
number, morphology and type of naevi is a strong indicator of melanoma risk, with 42% of 
people with high mole counts (>60) developing melanoma (Olsen et al., 2010), and 20-50% 
melanomas arise from pre-existing naevi (Goldstein and Tucker, 2013). There are likely to be 
differences in gene expression associated with dysplastic features, although whether this 
remains a useful diagnosis in terms of melanoma risk is less certain. The set of most 
discriminatory markers represent genes with known contribution to melanoma 
transformation.  BRAF
V600E
 expression in melanocytes induces p16 expression, a major 
factor in the senescence phenotype and proliferative arrest (Gray-Schopfer et al., 2006; 
Michaloglou et al., 2005).  Activation of PI3K-ATK pathway, commonly through 
mutation/down-regulated expression of PTEN (Dankort et al., 2009; Vredeveld et al., 2012) 
or increased AKT3 (Cheung et al., 2008)  bypasses OIS and promotes tumorigenesis.  Thus 
loss of PTEN and nuclear p16 are expected contributors to transformation.  Increased N-
Cadherin has been associated with loss of PTEN signalling (Lade-Keller et al., 2013), and the 
loss of nuclear -Catenin may be related to gain of nuclear N-Cadherin (Grossmann et al., 
2013). Although the accumulation of nuclear -Catenin is commonly associated with 
transformation in many cancer types, its role in melanoma is less clear (Webster and 
Weeraratna, 2013).  Loss of nuclear -Catenin has been observed previously in melanomas 
(Bachmann et al., 2005).  The reciprocal nature of nuclear -Catenin and N-Cadherin was a 
common, but not a invariable, feature in the lesions examined in the current study. The 
association of transformation with increase lymphangiogenesis (D240 vessels) is unclear.  
The Ki67 staining was also of interest particularly in the naevi. It appeared that the higher the 
number of more transformation markers accumulated by a naevus, the higher the chance of 
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there being evidence of proliferation. Unsurprisingly, all of the melanomas with very few 
exceptions were highly proliferative.  
 
This data indicates that although naevus transformation to melanoma is an uncommon 
event (the overall risk of any individual naevus developing into a melanoma ~1/30,000 (Tsao 
et al., 2003)), naevi represent a reservoir of premalignant cells. The immunostaining also 
showed that in the majority of cases, the changes in marker staining were relatively uniform 
across the naevi, only in few cases was staining found to be localised to parts of a naevus.  
Thus the naevus represents a large reservoir of premalignant cells that require few further 
changes/mutations to acquire a fully transformed phenotype.  This is likely to be a multistep 
process rather than any single event being responsible for transformation.  There are also 
likely to be multiple pathways that can lead from naevus to melanoma.  This is apparent from 
the spread of melanoma staining patterns shown in the MCA analysis compared with the 
much tighter clustering of the naevus staining patterns. For example, multiple pathways have 
been identified that can bypass BRAF/NRAS induced senescence, a major obstacle to 
transformation. These including metabolic rewiring through pyruvate dehydrogenase (PDH) 
(Kaplon et al., 2013), up-regulation of ribonucleotide reductase subunit M2 (RRM2) which is 
rate limiting for dNTP synthesis  (Aird et al., 2013), increased mTOR signalling  (Damsky et 
al., 2015),  and activation of the PI3K-ATK pathway  (Cheung et al., 2008; Dankort et al., 
2009; Vredeveld et al., 2012).  Dysregulation of any of these pathways could drive past the 
senescence arrest to promote transformation to melanoma, although it is likely that multiple 
pathways are involved.   
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 The existence of a subset of histologically benign naevi with elevated markers of 
transformation suggests that if a non-invasive means of identifying these can be developed, it 
may be present clinicians with an opportunity to focus their treatment decisions on these 
higher risk lesions.  This should translate into improved outcomes and less unnecessary 
excisions, particularly in high risk DNS population.   
 
Materials and Methods 
Selection of immunohistochemical markers 
A candidate gene approach based on extensive literature review was used to select a panel of 
20 potential molecular markers of transformation. Markers required a commercially available 
antibody for detection in formalin-fixed, paraffin embedded tissue. Selected markers had 
been previously implicated in the transformation to melanoma and covered a spectrum of 
roles in melanoma pathogenesis including markers of proliferation, cell differentiation, and 
structural proteins. The markers selected and antibodies used are reported in Supplementary 
Table S10.  
 
Immunohistochemistry 
Slides were deparaffinized and rehydrated through xylene to water. Antigen retrieval was 
performed with a five minute boiling cycle in 0.01M citrate buffer in a commercial decloaker. 
Peroxidase block was performed with 3% hydrogen peroxide for 15 minutes. Non-specific 
binding was blocked with donkey serum/bovine serum albumin in TBS for 30 minutes prior 
to overnight incubation with the primary antibody. The immunohistochemistry procedure was 
performed using an IMPRESS universal kit (Vector) according to the manufacturer’s 
guidelines. Vector ImmPACT NovaRED peroxidase substrate was applied as a chromogen 
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for visualization of the immunoreaction. Haematoxylin was used for counterstain. Negative 
controls were obtained by omitting the primary antibody. Positive controls were obtained 
using tissue sections known to be positive for the antibody in use. Specific staining by each 
of the antibodies assessed here was initially validated with the positive control tissue arrays, 
and positive controls were included for each antibody in conjunction with the TMA staining.  
Additionally, normal human skin (neonatal foreskin) was used a further control for normal 
skin staining of melanocytes and provide an indication of intensity of staining. Slides were 
mounted using ClearMount mounting solution (Invitrogen) and coverslipped with Xylene and 
Entellan (Merck Millipore) mounting media. They were then scanned using an Aperio slide 
scanner at 20x magnification.  
 
Immunohistochemistry Scoring 
Two experienced dermatopathologist (HPS and DL) independently reviewed biopsies in the 
initial set of 95 full width lesions.    In the few cases where there was disagreement in the 
diagnosis, they consulted to come to a consensus.  DL also independently reviewed the 
diagnosis of the TMA samples.  Two independent observers (BG, DL) performed a blinded 
evaluation of the immunohistochemically stained slides. Each antibody was scored according 
to a defined set of parameters specific to that marker. Overall intensity of immunoreactivity 
was evaluated using a stepwise scoring system (0 to 3+): 0 (negative): no staining; 1+/-: very 
weak staining; 2+ weak staining; 3+ moderate staining; or 4+ strong staining. Percentage of 
immunoreactive cells was evaluated using a stepwise scoring system (0-100%); 0: no cells 
stained; 1: 1-33% of cells stained; 2: 33-66% of cells stained; 3: >66% of cells stained. 
Nuclear, cytoplasmic and membranous staining were allocated a score of 0 or 1 indicating 
staining to be present or absent. TMA spots with a lack of tumor tissue or presence of 
necrosis or crush artifact were excluded from the analysis. In case of discordant scoring 
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results a consensus score was assigned. Features scored with each of the markers used is 
presented in Supplementary Table S11.  H scores were calculated as the product of the 
categorised intensity and categorised percentage cells stained.   
 
Tissue Microarray Analysis  
The TMA utilized in our study comprised 100 lesions, ranging from compound naevus to 
distant melanoma metastases The TMA consisted of triple-punch samples from formalin-
fixed, paraffin-embedded lesions through Melanoma Institute Australia (MIA; 
Supplementary Table S3). Lesions were categorized for analysis into six ordered classes; 
benign naevus, dysplastic naevus, thin melanoma (<1mm), thick melanoma (>1mm), lymph 
node metastasis and distant metastasis, based on histologic examination of the full width 
lesions undertaken at Melanoma Institute Australia. Markers that were qualitatively 
informative from the initial TMA analyses were tested across this TMA, as well as a selection 
of additional markers identified in our literature search. Marker assessments using the TMAs 
are reported in Supplementary Table S11. 
 
Full width section analysis 
A series of 35 lesions was obtained from TA, MT, IKK, FO in Turkey. This set comprised 35 
naevi on a spectrum of severely dysplastic to melanoma in situ and thin invasive melanoma. 
A series of 65 lesions was obtained from the Princess Alexandra Pathology Archives and 17 
lesions were obtained from MyLab Pathology (DL), and a separate validation cohort 62 
lesions were obtained from IQ Pathology (DL). Any melanocytic lesion excised in the past 
two years was considered for inclusion and lesions diagnosed as benign naevus, dysplastic 
naevus, thin or thick melanoma based on the reporting pathologist’s diagnostic report were 
selected randomly. Lesions were included if there was sufficient tissue to permit sectioning 
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and immunohistochemical analysis.  Histopathologic diagnosis was obtained by two authors’ 
(HPS, DL) review of the original H&E-stained sections in conjunction with pertinent 
demographic and clinical information ascertained from the available surgical pathology 
report. Lesions were diagnosed as benign naevi, dysplastic naevi, melanoma in situ, thin 
melanoma (<1mm) or thick melanoma (>1mm), or other. All tissue samples were acquired 
following ethics approval from the University of Queensland (ref: 2011001201). Specimen 
details are included in Supplementary Table S12. Only informative immunohistochemical 
markers in the tissue microarray study were examined. Several new markers were included. 
CD31 and D240 were not tested on the TMA as these are extratumoral markers and their 
expression is seen in the stroma surrounding the lesion – tissue that is not included in a 
microarray sample.  In addition, Osteopontin (OPN), Ki67, N-Cadherin, BRAF V600E and 
PTEN were not tested on the TMA due to limited availability of TMA material. Markers 
tested across the full-width specimen set are shown in Supplementary Table S5.   
 
Data preprocessing 
A common problem in large-scale immunohistochemical studies is missing values in the data 
matrix due to missing or damaged tissue specimens. In this study, 9.3% of values were 
missing. Patient data with missing data points was excluded from the analysis. Prior to 
analysis, p16 score and p16 % cells were converted to a binary scale (0,1) such that whenever 
values are 1 they were changed to a value of 1. These changes were made to better reflect 
the biology of p16 in that it is either present or absent in melanocytic lesions.  
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Statistical Analysis  
Statistical analyses were conducted using the R statistical software version 2.11 using both 
univariate and multivariate statistical methods. For each categorical variable Fisher’s exact 
univariate tests were performed to test the association between the counts observed in each 
category of the variable of interest, and the outcome (lesion diagnoses). For continuous 
variables (e.g. D240 vessels, Ki67), a non parametric Mann-Whitney test was performed to 
test the difference in medians between the different lesion diagnoses.  P-values from those 
univariate tests were corrected using the Benjamini and Hochberg  (Benjamini and Hochberg, 
1995) approach to control the false discovery rate (FDR). 
 
 Multivariate analyses were performed on all categorical variables only. For those 
analyses, the variable Ki67 and D240 were converted to categorical variables by selecting 
obvious cutoff points in plots of data distribution blinded for lesion diagnosis.  Cut offs of 
three D240 vessels per 10X high powered field, and 2% Ki67 positive nuclei were chosen 
(Supplementary Figure S5). Supervised multivariate analyses were performed using the 
Machine Learning approach Random Forest (RandomForest R package) (Breiman, 2001; 
Liaw, 2002) in order to identify biomarkers discriminating the different lesions, or assess the 
discriminative ability of the Transformation score. The top discriminate biomarkers were 
ranked according to a predictive accuracy measure as a direct output from the random forest 
analysis. A stability analysis was then performed using 10-fold cross-validation repeated 100 
times to assess whether those top biomarkers were repeatedly selected across those runs. 
Unsupervised multivariate analysis was performed using Multiple Correspondence Analysis 
(MCA) (Greenacre, 2007), the counterpart of Principal Component Analysis for categorical 
variables, as a mean to cluster the lesions with no a priori on their diagnosis. MCA was based 
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on significant staining parameters previously identified in the univariate and Random Forest 
analyses. 
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Tables: 
Table 1: Univariate analysis of marker of naevus transformation to thin primary melanoma 
 
 
 
 Variable Test p-value 
Association with malignant 
phenotype 
1 D240 vessels 
Mann-
Whitney 
1.87E-23 
Increase number of vessels per 
10X hpf 
2 PTEN % cells 
Fisher's 
exact 
1.09E-08 Loss of % cells stained 
3 N-Cadherin nuclear Fisher's 2.20E-08 Increase in nuclear staining 
4 PTEN score Fisher's 4.09E-07 Loss of intensity of staining 
5 Ki67  
Mann-
Whitney 
5.27E-07 Increased % cells stained 
6 -Catenin nuclear Fisher's 1.42E-05 Loss of nuclear staining 
7 p16 nuclear Fisher's 1.75E-04 Loss of nuclear staining 
8 N-Cadherin % cells Fisher's 9.47E-03 Increase in % cells stained 
9 N-Cadherin score Fisher's 1.17E-02 Increase in intensity of staining 
10 HMGB2 score Fisher's 4.17E-02 Loss of intensity of staining 
11 CD68 number of cells Fisher's 4.21E-02 
Increase in number of cells 
per10X hpf 
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Table 2: Transformation score.  Parameters used to identify transformed melanoma.  The 
Transformation score is the sum of the seven individual scores, where a score of 1 was 
assigned in the following cases: 3  or more D240 vessels, score of 2 or more Ki67, PTEN H 
score ≤ 4, the presence of nuclear N-Cadherin staining, absence of nuclear p16, absence 
nuclear -Catenin staining, and elastosis score greater than 1 to give  a maximum score of 
seven.   
 
 
 
Variable Score = 1 if 
1 D240 vessels ≥ 3 
2 Ki67 ≥ 2 
3 PTEN  H score < 4 
4  N-Cadherin nuclear yes 
5  -Catenin nuclear no 
6  p16 nuclear no 
7 Elastosis score >1 
 
 
 
Table 3: Random Forest analysis to assess the combined seven marker Transformation score 
ability to discriminate and predict naevus and melanoma. Analysis was performed on the 
pooled naevi and pooled melanomas. Classification error rate was 16% as detailed in the 
contingency matrix (real classes indicated in rows, and random forest predictions based on 
500 bootstrap trees indicated in columns). 
 
 
 
 
 
  Naevus Melanoma 
Naevi 22 10 
Melanomas 0 30 
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Titles and legends to figures  
Figure 1:  
Typical staining patterns for p16 and HMGB2 in naevus and thin primary melanomas.  In 
both cases, there is a reduction in the strong nuclear staining in the melanomas.  
 
Figure 2: 
MCA sample plot showing only the samples coloured according to diagnosis type (1, benign 
naevus; 2, dysplastic naevus; 3 melanoma in situ; 4, thin primary melanoma; 5, thick primary 
melanoma). Types 1-2 can be well separated from Types 4-5 using the first component (x-
axis), while Type 3 samples are spread across the two clusters. 
 
Figure 3: 
Typical staining pattern for the indicated markers in naevi and thin primary melanomas.   
 
Figure 4: 
Transformation score calculated for each lesion in the learning (A) and validation sets (B) 
using the criteria in Table 2.  The colored marks indicated the percentage of Ki67 positive 
cells in each lesion.  * p<0.05, ** p<0.005, *** p<0.001.   
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